AZD1222
AZD1222, also known as Covishield or ChAdOx1 nCoV-19, is a COVID-19 vaccine developed by Oxford University and AstraZeneca given by intramuscular injection. As of December 2020, the vaccine candidate is undergoing Phase III clinical research. On 30 December 2020 the vaccine was approved for use in the UK’s vaccination programme.
